FIELD: biotechnology.
SUBSTANCE: versions of antibodies that bind to human CD74 versions 1 and 2 are presented. A recombinant host cell is provided which generates the said antibody version. Compositions for cancer treatment and prevention containing this antibody version are provided.
EFFECT: group of inventions allows efficient and selective destruction of tumour cells expressing CD74, which can be used in cancer treatment.
55 cl, 15 dwg, 14 tbl, 25 ex
| Title | Year | Author | Number |
|---|---|---|---|
| "ANTIBODY-DRUG" CONJUGATES | 2012 |
|
RU2624141C2 |
| ANTIBODIES SPECIFIC TO BTN2 AND THEIR APPLICATIONS | 2018 |
|
RU2794996C2 |
| THERAPEUTIC ANTIBODIES AND THEIR APPLICATION | 2016 |
|
RU2722381C2 |
| ALPHA5-BETA 1 ANTIBODIES AND USING THEM | 2009 |
|
RU2528736C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2013 |
|
RU2599417C2 |
| INTERFERON ALPHA 1 RECEPTOR ANTIBODIES AND USE THEREOF | 2005 |
|
RU2600884C2 |
| HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR PROGRAMMED CELL DEATH 1 (PD1) PROTEIN AND METHODS OF TREATING CANCER WITH USING ANTI-PD1 ANTIBODIES EITHER INDIVIDUALLY, OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2006 |
|
RU2494107C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2006 |
|
RU2406760C2 |
| ANTI-CXCR4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2014 |
|
RU2675516C2 |
| ANTIBODIES OF INTERFERON ALFA RECEPTOR 1 AND THEIR APPLICATION | 2005 |
|
RU2412202C2 |
